z-logo
open-access-imgOpen Access
Clinical and genealogical study of patients with endometrial hyperplasia and cancer in Kyiv region
Author(s) -
L G Buchynska,
N. M. Hlushchenko,
I P Nesina,
N. P. Yurchenko
Publication year - 1970
Publication title -
faktori eksperimentalʹnoï evolûcìï organìzmìv
Language(s) - English
Resource type - Journals
eISSN - 2415-3826
pISSN - 2219-3782
DOI - 10.7124/feeo.v21.855
Subject(s) - endometrial cancer , endometrial hyperplasia , medicine , atypical hyperplasia , menopause , gynecology , hyperplasia , pedigree chart , cancer , obstetrics , oncology , biology , biochemistry , gene
Aim. To determine the informativeness of genealogical and morphological characteristics of patients with endometrial hyperplasia and cancer. Methods. Clinical and genealogical analysis, mathematical and statistical method, method of selection of informative factors – Kullback informativeness criterion. Results. Information about the health of 243 first- and 413 second-degree relatives was received from 50 patients with endometrial hyperplasia. Data on 2026 first- and 3685 second-degree relatives was also obtained from 413 patients with endometrial cancer. It was found that the most significant clinical indicators (I>0,5) for risk of endometrial cancer are the next: age over 60 years (I=2,76); presence of cancer of female reproductive organs and gastrointestinal tract in pedigrees of patients with atypical hyperplasia (I=1,51); duration of menopause more than 11 years (I=1,40); dysfunctional uterine bleeding (I=0,85); III–IV class of obesity (I=0,59); bleeding in menopause (I=0,55). Conclusions. Predicative effectiveness of studies of family histories of patients with atypical endometrial hyperplasia was substantiated that has clinical value and allow assessing the personalized risk of endometrial cancer. Keywords: endometrial hyperplasia and cancer, clinical and genealogical analysis, pedigrees.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here